Recruiting

MiaGBGut and Oral Microbiome's Role in Cognitive Health and Decline

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This observational study aims to assess the diversity of gut microbiome in different groups including young healthy adults, cognitively healthy older adults, individuals with mild cognitive impairment, and those with Alzheimer's disease/dementia, using stool samples. The study will also track annual changes in gut microbiome diversity for some groups.

What is being collected

Data Collection

Collected from today forward - Prospective
DNA Samples
Who is being recruted

Mental Disorders+11

+ Brain Diseases

+ Central Nervous System Diseases

Over 18 Years
+6 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.
Observational
Study Start: September 2021
See protocol details

Summary

Principal SponsorUniversity of South Florida
Study ContactShalini Jain, PhDMore contacts
Last updated: September 2, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: September 16, 2021

Actual date on which the first participant was enrolled.

The Microbiome in Aging Gut and Brain (MiaGB) Study is a multisite observational study investigating relationships among the gut and oral microbiome, cognitive function, microbial metabolites, intestinal permeability, inflammation, and other biological characteristics associated with aging and cognitive impairment. The study consists of two interconnected phases. Phase 1 is a baseline cross-sectional assessment. A total of 700 participants are planned, including 100 young healthy adults, 300 cognitively healthy older adults, 200 older adults with mild cognitive impairment (MCI), and 100 older adults with Alzheimer's disease or related dementia. Baseline assessments include demographic and medical history information, cognitive function, dietary information, and selected physical function assessments. Biological samples may include stool, oral swabs, saliva, blood, and urine. Laboratory analyses may include characterization of the gut and oral microbiome, metabolomics, markers of intestinal permeability and inflammation, proteomics, transcriptomics, genetic analyses, mitochondrial function, immunophenotyping, and other protocol-specified biological assessments. These data will be examined to determine whether microbial and biological patterns differ among participants with different levels of cognitive function. Phase 2 is a prospective longitudinal follow-up. Young healthy adults, cognitively healthy older adults, and participants with MCI will be reassessed approximately annually for up to 5 years. Longitudinal assessments will be used to evaluate whether changes in the microbiome and related biological measures are associated with changes in cognitive function and whether these measures may help identify individuals at increased risk of cognitive decline. Participants with Alzheimer's disease or related dementia will undergo baseline assessment only and will not participate in the 5-year longitudinal follow-up. This is an observational study. Participants are not assigned to a drug, biological product, behavioral treatment, or other research intervention.

Principal SponsorUniversity of South Florida
Study ContactShalini Jain, PhDMore contacts
Last updated: September 2, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

700 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.


Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Mental DisordersBrain DiseasesCentral Nervous System DiseasesCognition DisordersNervous System DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsNeurodegenerative DiseasesNeurocognitive DisordersTauopathiesAlzheimer DiseaseDementiaInflammationCognitive Dysfunction

Criteria

3 inclusion criteria required to participate
Age 18-60 years for young healthy participants, or age 60 years and older for older adult participants

Normal cognitive function Mild cognitive impairment (MCI) Alzheimer's disease or Alzheimer's disease-related dementia Able to participate in the informed consent process as applicable. For participants unable to provide informed consent because of cognitive impairment, consent may be obtained from a legally authorized representative (LAR) according to the approved protocol

Participants meeting one of the following cognitive categories

3 exclusion criteria prevent from participating
Antibiotic use within the past 30 days. Diarrhea, vomiting, and/or food poisoning within the past 30 days. History of inflammatory bowel disease. Body mass index (BMI) greater than 45 kg/m^2 or less than 18 kg/m^2. Weight loss of more than 10 pounds within the past 2 weeks

History of brain or gastrointestinal surgery within the past 5 years. History of cancer and/or cancer treatment within the past 5 years, except non-melanoma skin cancer

History of systemic cancer treatment within the past 5 years. Neurological disorders including epilepsy, Parkinson's disease, or amyotrophic lateral sclerosis

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

4 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Department of Neurosurgery and Brain and Spine and Faculty of USF Center for Microbiome Re-search, Microbiomes Institute

Tampa, United StatesOpen Department of Neurosurgery and Brain and Spine and Faculty of USF Center for Microbiome Re-search, Microbiomes Institute in Google Maps
Recruiting
One Study Center